ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
0.9664
-0.0028
(-0.29%)
Closed May 25 4:00PM
0.964
-0.0024
(-0.25%)
After Hours: 7:46PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.964
Bid
0.96
Ask
0.999
Volume
3,300,354
0.946 Day's Range 0.9989
0.851 52 Week Range 5.53
Market Cap
Previous Close
0.9692
Open
0.9692
Last Trade Time
Financial Volume
$ 3,217,040
VWAP
0.974756
Average Volume (3m)
7,096,385
Shares Outstanding
109,336,211
Dividend Yield
-
PE Ratio
-0.40
Earnings Per Share (EPS)
-2.44
Revenue
3.6M
Net Profit
-266.58M

About bluebird bio Inc

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's reven... bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
bluebird bio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker BLUE. The last closing price for bluebird bio was $0.97. Over the last year, bluebird bio shares have traded in a share price range of $ 0.851 to $ 5.53.

bluebird bio currently has 109,336,211 shares outstanding. The market capitalization of bluebird bio is $106.06 million. bluebird bio has a price to earnings ratio (PE ratio) of -0.40.

bluebird bio (BLUE) Options Flow Summary

Overall Flow

Bearish

Net Premium

-34k

Calls / Puts

0.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

BLUE Latest News

Investors in bluebird bio, Inc. Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights - BLUE

Investors in bluebird bio, Inc. Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights - BLUE PR Newswire NEW YORK, May 21, 2024 NEW YORK, May 21, 2024 /PRNewswire/ -- The...

Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, May 14, 2024 NEW YORK, May 14, 2024 /PRNewswire/ -- The...

bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

- First patient start (cell collection) for LYFGENIA completed – - 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio, Inc. Lawsuit - BLUE

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio, Inc. Lawsuit - BLUE PR Newswire NEW YORK, May 7, 2024 NEW YORK, May 7, 2024 /PRNewswire/...

bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events

bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET. To participate in the...

bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy

bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.066-6.407766990291.031.070.9341039770.99308887CS
40.05385.910788837620.91021.230.85167363380.98618204CS
12-0.436-31.14285714291.41.670.85170963851.18597217CS
26-2.786-74.29333333333.755.530.851104028651.60371821CS
52-2.756-74.08602150543.725.530.85171352742.10674151CS
156-30.766-96.961865742231.7335.58830.85149723714.6880742CS
260-121.756-99.2144719687122.72143.980.851343547012.00939083CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

BLUE Discussion

View Posts
Moose412 Moose412 10 hours ago
Irrefutable...changed my mind, had to increase the position.
👍️0
Monksdream Monksdream 7 days ago
BLUE 10 day hourly chart
👍️0
Moose412 Moose412 1 week ago
You should post more. I have faith in Gina Wang's rating, and I also believe whether or not the first patient receiving Lyfgenia needs to have a second cell collection is going to be influential in significant ways.
👍️ 2
Rubraquercus Rubraquercus 2 weeks ago
Your $5 - $10 prediction for/in 2025 will require every bit of that $300 million revs confirmation and then some. In the real world this is an easy double by the end of the year at $100 million (short putt). Thankfully I have been watching it for many years and went all in based on the $1 price and recent approval of the 3rd drug. $10 is doable late late next year at best in my safety first opinion
👍️ 2
stocksrising stocksrising 2 weeks ago
Q1 decent rev, but we need to get thru Q3 to truly see traction of all 3 indications to assume ~$300mm in revs…cash burn better than historical run rate , but I believe the 10k/Q overhang ( analyst asked about OPEX, P&L , etc) will persist until filed..these Analyst need to model all metrics but I remain positive as we get to 2nd half, 24’ …we need more color from management in 2nd half to move the needle towards $5pps to start , then $10 is probable in 2025 imho..GLTA
👍️ 1
johnhancoque johnhancoque 2 weeks ago
Cash relatively unchanged q over q. Starts on track for 105 in 2024. Revenue over 300 million based on current metrics and pricing. Headed back to $10.00 imho
👍️0
stocksrising stocksrising 2 weeks ago
Let’s all jump on the call starting at 8am

+1 (800) 715-9871
Conference ID 9768329.
👍️ 1 🤩 1
johnhancoque johnhancoque 2 weeks ago
It works and it's just starting to run. Once it begins, there is no looking back
👍️0
johnhancoque johnhancoque 2 weeks ago
I dont think less than $18.00 will be agreed upon for starter talks to BP. BLUE has a better drug than crsp and will outpace them on many levels including speed and cell collections due to the fact vertex must do 2 to 4 collections for every patient to our 1. Bluebird can get back over $100.00 on their own with patient investors imho
👍️0
Monksdream Monksdream 2 weeks ago
Seeking Alpha must be wrong
👍️0
Moose412 Moose412 2 weeks ago
Hmm. Coulda sworn I heard the bell. 17:34, 05.07.2024.
👍️0
Monksdream Monksdream 3 weeks ago
BLUE 10Q due after the bell per Seeking Alpha
T+1 settlement begins 5/28
👍️0
Moose412 Moose412 3 weeks ago
There are *THREE* approved curative therapies. Adrenoleukodystrophy, Beta Thalassemia, and Sickle Cell.

IMO, this should be at least $5. But there's that word: Future. Unknown.

Money is nice. Being able to live, and live pain free - that's much nicer.
👍️ 1
axelvento axelvento 3 weeks ago
if the drug works.....can be a runner!
👍️ 1
johnhancoque johnhancoque 3 weeks ago
Easy. Each patient is 3.1 million in revenue. Do the math and it's easy to see with 20,000 patients eligible in u.s.a. alone the revenue is in the 10s of Billions over next 5 to 10 years
👍️0
axelvento axelvento 3 weeks ago
First Patient Begins Newly Approved Sickle Cell Gene Therapy


https://www.nytimes.com/2024/05/06/health/sickle-cell-cure-first.html
👍️ 1
Moose412 Moose412 3 weeks ago
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
Published: May 06, 2024

https://www.biospace.com/article/releases/bluebird-bio-announces-completion-of-first-cell-collection-for-lyfgenia-gene-therapy/
👍️ 1
Moose412 Moose412 3 weeks ago
I can only answer by pointing to one operative word in my post, and that is undefined, for no one knows what it will bring. That word is "future".

As an early childhood survivor of an Astrocytoma and a recipient of blood transfusions prior to 1983, I have significant interest in all three of their drugs - from neurological issues to blood issues. Clearly, I have no shame and am not afraid.

Some call it investing, others call it gambling. I may sell, but I am inclined it "let it ride". If I sell, it is only bc I need liquidity. As with all ventures, one should not engage unless they are willing to lose it all. I can't afford to lose it all, but I'm still here. And I am grateful for that.

Finally, the major issue to contend with is bad actors. I assure you I am not - but I can only ask that people have faith that my actions and intentions are pure of heart.
👍️0
AstroKraken39 AstroKraken39 3 weeks ago
This is a very interesting stock. What is your unbiased opinion on price target for this year and 2025? The biggest fear is about cash burn rate and sustainability. How can they be cash flow positive?
👍️ 1
Moose412 Moose412 3 weeks ago
I'll tell you what I think, friend - I'm eager for earnings on the 7th, although I'm fairly positive we will not see them for another few weeks after that date. I think that the class action is going to fail, that patient starts across all three drugs is going to exceed the minimum forecast of...what was it, 80 patient starts?, and that BLUE is going to skyrocket in the future, becoming the talk of wall street.

At any rate, I'm not buying anymore, even though today is/was my calendar day to avoid making wash sales. I will say that I may sell at any given point in time - the volatility is nerve racking and times are getting tight, as it were.... But much like a certain other person, I like the stock. I like the stock a LOT.
👍️ 1 🫡 1
Moose412 Moose412 1 month ago
The Gross law firm has filed a class action lawsuit against Bluebird on behalf of shareholders who purchased between April 24 2023 and December 8 2023.

IMO, Blue has not committed the securities law violations alleged (which have not been named or enumerated, btw), and any lawsuit going forward should be filed against the FDA for their issuance of the "Blackbox" warning. Blue stated previously they intend to address the non-award of the PRV with the FDA. They should also be pursuing removal of the "Blackbox" warning; if the Blackbox warning had teeth, the clinical trial hold should never have been lifted in the first place - but the FDA vindicated BLUE from this previously. Furthermore, if BLUE did commit securities fraud (again, unspecified how), then that falls onto the regulatory agency moreso than BLUE, IMO.

Honestly - if not a single analyst anticipated the Blackbox warning, this is all a malignant waste of time by the FDA.

[ALLEGATIONS: According to the complaint, on December 8, 2023, Blue announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). However, the Lyfgenia approval came with a black box warning for haematological malignancies after two patients developed AML during the clinical trials. Analysts noted that they did not expect the black box warning or the absence of a priority review voucher. Following this news, Blue's stock price fell by $1.95 per share, or approximately 40% to close at $2.86 per share.]
👍️0
Moose412 Moose412 2 months ago
That seeking alpha article is behind a paywall, unfortunately. I'm sure I wouldn't be the only happy person if you posted the sentences that you find informative.

I believe in the power of BlueBird's medicines, but I am concerned about the shorts, as I've had a ridiculous amount of calls get just completely disintegrated by the pressure on this stock in the last 2.5 years. Hopefully, we find that Blue management is honest and also correct about their projections going forward. In addition to that, I'm keeping my fingers crossed that it is Hercules's goal to help facilitate the healthcare options that BLUE has created, and not to steal the entirety of the companies I.P. The agreement does hinge somewhat on the company trading, if I am correct in my calculations, above $2.63 USD for the preceding 30 days of the first day of any financial quarter.

I've lost out significantly to other companies' management teams over the years that were malignant, and I am deeply disturbed that BLUE eliminated the graphic of "Misc Undisclosed" from their pipeline page in the summer of '23. I'm disappointed they haven't addressed that, and have significant thoughts about addressing management over the issue myself. If any of these class action examinations have solid footing, that is one aspect that will be exposed.

I will be reducing my holdings, starting next week, by ~11% for tax harvesting purposes, but I am not going anywhere. I am hoping it tanks a bit more so I can keep more than 89% of my current holdings.
👍️0
Kallie Kallie 2 months ago
I hope you got in, I think it's worth it means nothing financially on the filing they found while securing financing and going over the books. The shorts were killing it but now that Hercules is the lender they have slowed and its non-dilutive financing. Read this transcript and watch the trading action if you haven't bought in yet. You can always buy calls. https://seekingalpha.com/article/4680564-bluebird-bio-inc-blue-q4-2023-earnings-call-transcript
❣️ 1
Lokotony Lokotony 2 months ago
OK! Checking out this error that's driving the price to a discount. Is this worth grabbing? I see that it used to be very high. I made the mistake of the same thing with other bios.....
👍️0
Monksdream Monksdream 2 months ago
BLUE under $2
👍️0
johnhancoque johnhancoque 3 months ago
Also, if it's the last quarter results that are public, why would this not be relevant might I ask? It's pretty standard in the industry for the last posted quarter results to stay relevant untill the next quarter or year end becomes publicly available. Do you know something the market does not on why the most recent c.c. would not be relevant??

Just wondering because the fact you question this would make one think you are fairly new to the investing world, which is fine, but I like to know where you're coming from that's all 🤔🤔🤔
👍️0
Moose412 Moose412 3 months ago
I have a hard time cheering someone who posts 4 month old info without a qualifier that it is 4 month old information. Couple that with your sudden appearance and flip from bearish to bullish within 3 weeks of each other....
👍️0
johnhancoque johnhancoque 3 months ago
I posted this because it was the last earnings on record. Q3 2023 results are a good indicator of growth and ramp for BLUE. The next c.c. is only weeks away for full year 2023 and fourth quarter 2023 which are normally combined into 1 earnings report and c.c.

Cheers
👍️0
Moose412 Moose412 3 months ago
Nov 7, 2023 at 8:00 AM EST has long since passed.

Why did you post this?
👍️0
Curt D Curt D 3 months ago
NICE!
👍️ 1
johnhancoque johnhancoque 3 months ago
https://investor.bluebirdbio.com/events/event-details/bluebird-bio-3rd-quarter-2023-results-call
👍️0
mrwilson31 mrwilson31 3 months ago
One of the top 25 Bio companies of 2024.

https://thehealthcaretechnologyreport.com/the-top-25-biotechnology-companies-of-2024/
👍️0
glenn1919 glenn1919 3 months ago
BLUE..................................................https://stockcharts.com/h-sc/ui?s=BLUE&p=W&b=5&g=0&id=p86431144783
👍️0
Moose412 Moose412 3 months ago
FDA Ramrod x2, + shorts.
👍️0
Coppatop Coppatop 3 months ago
Honestly -- what happened to this company?

I have never actually invested in BLUE but I have been following it for a while. I live near by and know some people who work for them. From what they could talk about and the press releases and journal articles i've read, it seems like they have an amazing technology that works to find solutions (cures) to unique problems. How did they go from trading over 200+ a share to this?
👍️0
Moose412 Moose412 3 months ago
That would be lovely, but what's your info?

At 190.4mm shares to 20 per, that's 3.8 Billion - or over 1000 drug sales at 2.75m avg. BLUE forecasted 80-100 sales this year.
👍️ 2
johnhancoque johnhancoque 3 months ago
Buyout is in the works. Very short time will be made public. Anything below $20.00 vote no. 3 blockbusters here
👍️ 1
glenn1919 glenn1919 3 months ago
BLUE.......................................https://stockcharts.com/h-sc/ui?s=BLUE&p=W&b=5&g=0&id=p86431144783
👍️0
Moose412 Moose412 3 months ago
I believe the bottom has come and gone. I wouldn't expect to see anything below $0.95 again.
👍️ 2 🤑 1
johnhancoque johnhancoque 3 months ago
On average, Wall Street analysts predict that Bluebird Bio's share price could reach $6.87 by Dec 21, 2024. The average Bluebird Bio stock price prediction forecasts a potential upside of 566.8% from the current BLUE share price of $1.03.
👍️0
Moose412 Moose412 3 months ago
This guy wants your shares of BLUE ruhl bad, me thinks.
👍️0
Monksdream Monksdream 4 months ago
BLUEnew 52 week low
🌈 1 🍆 1 👎️ 1 🤡 1 🩳 1
johnhancoque johnhancoque 4 months ago
Bottom is far from in. Amrn hit .65 cents just a few months ago. Sadly, blue won't recover imho
🥶 1
johnhancoque johnhancoque 4 months ago
Amrn dropped to .65 cents before making any recovery. Unfortunately, this is not bottom for bluebird bio
👍️0
johnhancoque johnhancoque 4 months ago
Reverse split inevitable here. Too many shares on the market now thanks to recent share sales. Float reduction is needed to move this bloated pig anywhere now unfortunately and that's why it continues below $1.00. Amrn hit .65 cents before it's bounce so prepare yourself this isn't even close to bottom
👍️0
Monksdream Monksdream 4 months ago
BLUE new 52 week low
🌈 1 🍆 1 👎️ 1 🤡 1 🩳 1
Monksdream Monksdream 4 months ago
BLUE new 52 week low
👍️0
Cosa Cosa 4 months ago
I seen this Bio and did little DD. But in the few minutes, one thing stood out. It causes cancer. You guys that did more DD might know something or see something that gives you confidence to invest here. I pass. Good luck guys.
👍️0
Cosa Cosa 4 months ago
I seen this Bio and did little DD. But in the few minutes, one thing stood out. It causes cancer. You guys that did more DD might know something or see something that gives you confidence to invest here. I pass. Good luck guys.
👍️0
Monksdream Monksdream 4 months ago
BLUE new 52 week low
👍️0

Your Recent History

Delayed Upgrade Clock